Evidence map›Paper›PMID 23620166›Full record

ArticleDrug safety2013

Baseline correction in parallel thorough QT studies.

Joanne Zhang, Qianyu Dang, Marek Malik

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Drug safety, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Practical guide to concentration-QTc modeling: a hands-on tutorial.Journal of pharmacokinetics and pharmacodynamics · 2025
    Article
  2. Concentration-QTc analysis with two or more correlated baselines.Journal of pharmacokinetics and pharmacodynamics · 2021
    Article
  3. Article
  4. Scientific white paper on concentration-QTc modeling.Journal of pharmacokinetics and pharmacodynamics · 2018
    Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Joanne ZhangDivision of Biometrics VI, Office of Biostatistics, Center of Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Bldg. #21 Room 4668, Silver Spring, MD 20993-0002, USA. Joanne.Zhang@fda.hhs.gov
Qianyu Dang
Marek Malik

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn parallel thorough QT (TQT) studies, it has been speculated that either baseline correction should be omitted, under the assumption that it only adds noise to the data, or a time-averaged baseline instead of a time-matched baseline correction should be considered in order to reduce the study variability.

objectiveThis study characterized the assumptions and implications of different baseline correction approaches in parallel TQT studies submitted for regulatory review. DATA AND

methods57 parallel TQT studies conducted between 2002 and 2009 in 5591 healthy volunteers were evaluated. Only moxifloxacin and placebo arms, including their baselines, were considered. The options of using no baseline correction, time-averaged baseline correction, and time-matched baseline correction were examined and compared.

resultsQTc values exhibited a diurnal pattern, with longer QTc intervals during sleep preserved when correcting for a time-averaged baseline. Post-dose and baseline QTc values were highly correlated (mean ρ = 0.80, range 0.56-0.98 and mean ρ = 0.79, range 0.50-0.96 in the placebo and moxifloxacin groups, respectively). The variability of raw QTc values was substantially larger than that of baseline-adjusted QTc values. The difference in the point estimate of QTc differences between moxifloxacin and placebo differed by up to ± 4 ms between the time-averaged and the time-matched baseline corrections. Statistical tests indicate that assumptions of time-averaged baseline and no baseline correction are not appropriate.

conclusionsBaseline correction in parallel TQT studies leads to more precise QTc estimates. Because of possible inaccuracy introduced by time-averaged baseline correction, the time-matched baseline correction appears to be preferable for a parallel TQT study to both reduce the intrinsic variability due to circadian patterns and obtain more accurate point estimates.

Indexed as

Heart Function TestsAdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsAza CompoundsCardiotoxinsCardiovascular AgentsCircadian RhythmData Interpretation, StatisticalElectrocardiography, AmbulatoryFemaleFluoroquinolonesHumansInvestigational New Drug ApplicationAnti-Bacterial AgentsAza CompoundsCardiotoxinsCardiovascular AgentsFluoroquinolonesMoxifloxacinQuinolines

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.